trending Market Intelligence /marketintelligence/en/news-insights/trending/4zkp3vzyo-egdwhwmynaqg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

UroGen Pharma appoints former Sucampo CFO as finance chief


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

UroGen Pharma appoints former Sucampo CFO as finance chief

UroGen Pharma Ltd. named Peter Pfreundschuh, the former CFO of Sucampo Pharmaceuticals Inc., as its finance chief.

Pfreundschuh, who has 20 years of executive experience, will take charge from Aug. 20. As Sucampo's CFO, he was involved in the company's $1.2 billion acquisition by Mallinckrodt.

Pfreundschuh has served in various roles ranging from finance, commercial operations and business development within the pharmaceutical industry. He is a director of Speratus Therapeutics Inc. and GitBasic LLC.

Stephen Mullennix, who has been UroGen Pharma's interim CFO since June 2018, will continue as its COO.

UroGen Pharma is headquartered in Israel and develops non-surgical treatments for diseases of the urinary tract and male reproductive tract, including anti-cancer products.